Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroups
Related Experiment Video
Updated: Oct 7, 2025
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Baris Gencer1, Alon Eisen2, David Berger2
1TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, and Department of Medicine, Harvard Medical School, Boston, MA; Cardiology Division, Geneva University Hospitals, Geneva, Switzerland; Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
Insights
Edoxaban demonstrated superior efficacy and safety compared to warfarin in high-risk atrial fibrillation patients. This novel anticoagulant offers improved net clinical outcomes, especially in patients with multiple risk factors.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Atrial fibrillation (AF) management requires effective anticoagulation, particularly in high-risk patients.
- Warfarin, a traditional anticoagulant, has limitations in efficacy and safety, especially in specific patient subgroups.
- Identifying safer and more effective alternatives to warfarin is crucial for improving patient outcomes.
Purpose of the Study:
- To compare the efficacy and safety of edoxaban versus warfarin in high-risk subgroups of patients with atrial fibrillation.
- To evaluate the net clinical outcome (NCO), a composite of stroke/systemic embolism, major bleeding, or death, across different risk strata.
- To assess the benefit of edoxaban in patients with specific high-risk features.
Main Methods:
- The ENGAGE AF-TIMI 48 trial randomized 21,105 AF patients with CHADS2 score >2 to higher-dose edoxaban regimen (HDER), lower-dose edoxaban regimen (LDER), or warfarin.
- Patients were followed for a median of 2.8 years, with NCO as the primary outcome.
- Multivariable risk-stratification analysis categorized patients based on the number of high-risk features.
Main Results:
- Warfarin showed the highest NCO rates in patients with malignancy, increased fall risk, and very low body weight.
- NCO rates in the warfarin arm significantly increased with the number of high-risk factors (0 to >4).
- Edoxaban (both HDER and LDER) demonstrated significant reductions in NCO compared to warfarin across most subgroups, with increasing absolute risk reductions favoring edoxaban as the number of high-risk features increased.
Conclusions:
- Edoxaban offers a safer and more effective alternative to warfarin for high-risk AF patients.
- Substitution of warfarin with edoxaban can improve clinical outcomes, particularly in patients with multiple risk factors.
- Addressing the underuse of anticoagulation in high-risk AF patients through effective alternatives like edoxaban is a key opportunity for improved care.
Background:
To compare the efficacy and safety of edoxaban vs warfarin in high-risk subgroups.
Methods:
ENGAGE AF-TIMI 48 was a multicenter randomized, double-blind, controlled trial in 21,105 patients with atrial fibrillation (AF) within 12 months and CHADS2 score >2 randomized to higher-dose edoxaban regimen (HDER) 60 mg/reduced 30 mg, lower-dose edoxaban regimen (LDER) 30 mg/reduced 15 mg, or warfarin, and followed for 2.8 years (median). The primary outcome for this analysis was the net clinical outcome (NCO), a composite of stroke/systemic embolism events, major bleeding, or death. Multivariable risk-stratification analysis was used to categorize patients by the number of high-risk features.
Results:
The annualized NCO rates in the warfarin arm were highest in patients with malignancy (19.2%), increased fall risk (14.0%), and very-low body weight (13.5%). The NCO rates increased with the numbers of high-risk factors in the warfarin arm: 4.5%, 7.2%, 9.9% and 14.6% in patients with 0 to 1, 2, 3, and >4 risk factors, respectively (Ptrend <0.001). Versus warfarin, HDER was associated with significant reductions of NCO in most of the subgroups: elderly, patients with moderate renal dysfunction, prior stroke/TIA, of Asian race, very-low body weight, concomitant single antiplatelet therapy, and VKA-naïve. With more high-risk features (0->4+), the absolute risk reductions favoring edoxaban over warfarin increased: 0.3%->2.0% for HDER; 0.4%->3.4% for LDER vs warfarin (P = .065 and P < .001, respectively).
Conclusions:
While underuse of anticoagulation in high-risk patients with AF remains common, substitution of effective and safer alternatives to warfarin, such as edoxaban, represents an opportunity to improve clinical outcomes.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:29Venous Thrombosis III: Interprofessional Care
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
01:30Venous Thrombosis IV: Nursing Management